Fennec Pharmaceuticals Inc. filings document formal disclosures for its commercial specialty pharmaceutical business, PEDMARK® product updates, and Nasdaq-listed common shares. Recent Form 8-K reports cover financial results, scientific presentations and investigator-sponsored studies involving sodium thiosulfate injection, and a license agreement resolving litigation tied to a proposed generic version of PEDMARK.
The company’s proxy materials cover director elections, board composition, executive compensation, equity awards, and shareholder voting matters. Other current reports disclose governance changes, registered common shares with no par value, and exhibits furnished with press releases concerning business, clinical, and product-related developments.
Rosty Raykov, a director of Fennec Pharmaceuticals Inc. (FENC), reported a sale of 10,000 common shares on 09/04/2025 at a reported price of $8.92 per share. The Form 4 indicates the sale was made pursuant to a 10b5-1 plan dated August 23, 2024. Following the reported transaction, Mr. Raykov beneficially owns 51,086 shares, held directly. The filing is a routine insider reporting disclosure of this transaction.
Robert Andrade, Chief Financial Officer of Fennec Pharmaceuticals, reported a Form 4 disclosing a transaction dated 08/31/2025 in which 2,431 common shares were acquired at a reported price of $0. The filing explains these shares were released from restriction and are from awards originally granted on 3/31/2023 and 5/16/2024. After this transaction Andrade beneficially owns 168,244 common shares. The Form 4 was signed by Andrade on 09/02/2025. The disclosure is a routine insider vesting event rather than a cash market purchase or sale.
FENNEC PHARMACEUTICALS INC. (FENC) director Rosty Raykov reported a Form 4 disclosing a change in beneficial ownership on 08/31/2025. Mr. Raykov acquired 5,208 common shares at a reported price of $0, increasing his total beneficial ownership to 61,086 shares. The filing explains these shares were released from restriction and originate from equity awards granted on 03/31/2023 and 05/16/2024. The Form 4 was filed by one reporting person and is signed on 09/02/2025. No derivative transactions or cash purchases are reported; the activity reflects restricted share vesting or release rather than an open-market purchase.